Free Trial

Eli Lilly and Company (LLY) Stock Forecast & Price Target

Eli Lilly and Company logo
$812.79 +0.36 (+0.04%)
As of 09:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
9
Buy
16

Based on 25 Wall Street analysts who have issued ratings for Eli Lilly and Company in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 25 analysts, 9 have given a hold rating, 15 have given a buy rating, and 1 has given a strong buy rating for LLY.

Consensus Price Target

$938.61
15.48% Upside
According to the 25 analysts' twelve-month price targets for Eli Lilly and Company, the average price target is $938.61. The highest price target for LLY is $1,190.00, while the lowest price target for LLY is $700.00. The average price target represents a forecasted upside of 15.48% from the current price of $812.79.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for LLY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Eli Lilly and Company and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LLY Analyst Ratings Over Time

TypeCurrent Forecast
10/23/24 to 10/23/25
1 Month Ago
9/23/24 to 9/23/25
3 Months Ago
7/25/24 to 7/25/25
1 Year Ago
10/24/23 to 10/23/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
15 Buy rating(s)
14 Buy rating(s)
16 Buy rating(s)
16 Buy rating(s)
Hold
9 Hold rating(s)
9 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$938.61$939.61$1,012.56$1,002.24
Forecasted Upside15.48% Upside25.74% Upside24.74% Upside10.99% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

LLY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LLY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Eli Lilly and Company Stock vs. The Competition

TypeEli Lilly and CompanyMedical CompaniesS&P 500
Consensus Rating Score
2.68
2.33
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside15.55% Upside1,456.32% Upside12.70% Upside
News Sentiment Rating
Positive News

See Recent LLY News
Neutral News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/20/2025BMO Capital Markets
4 of 5 stars
 Boost TargetOutperform$840.00 ➝ $930.00+15.74%
10/16/2025Guggenheim
3 of 5 stars
Reiterated RatingBuy$948.00+14.74%
10/14/2025Erste Group Bank
3 of 5 stars
 UpgradeHoldBuy
10/10/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$876.00 ➝ $879.00+5.51%
10/9/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set TargetOverweight$925.00+9.40%
10/8/2025Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingHold (C+)
10/3/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$1,028.00 ➝ $1,023.00+24.65%
10/1/2025HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Target$700.00 ➝ $800.00-4.81%
9/17/2025Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuyHold$970.00 ➝ $830.00+8.70%
9/16/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$1,100.00 ➝ $1,050.00+40.33%
8/27/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeModerate SellHold
8/17/2025Daiwa Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformNeutral$700.00-0.22%
8/17/2025Daiwa America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeStrong-BuyHold
8/14/2025DZ Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldStrong-Buy
8/11/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$1,010.00 ➝ $900.00+40.51%
8/8/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$1,050.00 ➝ $895.00+42.63%
8/7/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeStrong-BuyHold
8/7/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperformMarket Perform$715.00+11.07%
5/1/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight
2/3/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$1,029.00 ➝ $1,038.00+27.51%
1/28/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$1,250.00 ➝ $1,190.00+47.25%
12/10/2024Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy$997.00+24.17%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageOutperform$1,000.00+27.23%
11/4/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
10/31/2024Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetOverweight$1,025.00 ➝ $975.00+16.30%
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$1,100.00+20.04%
9/5/2024Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
6/24/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$994.00 ➝ $1,015.00+12.98%
5/14/2024Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$770.00 ➝ $840.00+11.04%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:35 AM ET.


Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, October 22, 2025. Please send any questions or comments about these Eli Lilly and Company pros and cons to contact@marketbeat.com.

Eli Lilly and Company
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

  • The current stock price is around $720, reflecting strong market interest and potential for growth.
  • Recent insider purchases indicate confidence in the company's future, with executives acquiring shares at significant values.
  • Analysts have upgraded their ratings on Eli Lilly and Co, with many recommending a "buy" due to positive earnings forecasts.
  • The company has set ambitious earnings per share (EPS) guidance for FY 2025, suggesting strong financial performance ahead.
  • With a diverse portfolio of human pharmaceuticals, Eli Lilly and Co is well-positioned to capitalize on market opportunities globally.

Eli Lilly and Company
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Eli Lilly and Co for these reasons:

  • Despite recent upgrades, some analysts have issued "hold" ratings, indicating caution about the stock's short-term performance.
  • The stock has seen fluctuations, which may indicate volatility and risk for investors looking for stable returns.
  • Insider ownership is relatively low at 0.14%, which may suggest less alignment between management and shareholder interests.
  • Market competition in the pharmaceutical sector is intense, which could impact Eli Lilly and Co's market share and profitability.
  • Potential regulatory challenges could arise, affecting the approval and marketability of new products.

LLY Forecast - Frequently Asked Questions

According to the research reports of 25 Wall Street equities research analysts, the average twelve-month stock price forecast for Eli Lilly and Company is $938.61, with a high forecast of $1,190.00 and a low forecast of $700.00.

25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last twelve months. There are currently 9 hold ratings, 15 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LLY shares.

According to analysts, Eli Lilly and Company's stock has a predicted upside of 15.48% based on their 12-month stock forecasts.

Over the previous 90 days, Eli Lilly and Company's stock had 4 upgrades and 3 downgrades by analysts.

Analysts like Eli Lilly and Company more than other "medical" companies. The consensus rating for Eli Lilly and Company is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how LLY compares to other companies.


This page (NYSE:LLY) was last updated on 10/23/2025 by MarketBeat.com Staff
From Our Partners